TYME

Tyme, Inc. (NASDAQ: TYME) is an emerging biotechnology company developing Cancer Metabolism-Based Therapies (CMBTs™) designed to be broadly effective across multiple tumor types while maintaining patient quality of life and relatively low toxicity. Unlike targeted therapies that aim to modulate specific pathways within cancer, Tyme’s approach seeks to exploit the innate metabolic requirements of cancer cells, disrupt their defenses, leading to cell death and exposure to the body's immune system.